Day One Biopharmaceuticals pany(DAWN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Day One Reports Third Quarter 2024 Financial Results and Corporate Progress Achieved $20.1 million in OJEMDA TM (tovorafenib) net product revenue Ended the third quarter with$558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, October 30, 4:30 p.m. Eastern Time BRISBANE, Calif., Oct. 30, 2024 – Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and co ...